PMID- 21906451
OWN - NLM
STAT- MEDLINE
DCOM- 20131029
LR  - 20110912
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 33
IP  - 4
DP  - 2011 Aug
TI  - [Prevention of platelet transfusion refractoriness and HLA alloimmunization by 
      leukocyte filtered platelet transfusion: a meta analysis].
PG  - 412-20
LID - 10.3881/j.issn.1000-503X.2011.04.013 [doi]
AB  - OBJECTIVE: To compare and assess the effectiveness of leukocyte-filtered platelet 
      and standard platelet concentrates transfusion in preventing platelet transfusion 
      refractoriness (PTR) and human leukocyte antigen (HLA)-alloimmunization. METHODS: 
      Randomized controlled trials (RCTs) or quasi-RCTs comparing leukocyte-filtered 
      platelet with standard platelet concentrates transfusion (up to December 31, 
      2009) were searched and identified from Medline, EMBASE, The Cochrane Library, 
      and CBM. A meta-analysis was conducted with Cochrane Collaboration's RevMan 5. 0. 
      RESULTS: The search identified 558 citations in total, in which 7 articles in 
      English were finally included in the meta-analysis. The analysis showed that 
      compared with standard platelet concentrates transfusion, leukocyte-filtered 
      platelet transfusion significantly decreased PTR [ RR = 0. 59, 95% CI (0. 42, 0. 
      82) , P = 0. 002 ] and HLA-alloimmunization [ RR = 0. 49,95% CI (0. 33, 0. 74) , 
      P =0. 0006]. Subgroup analysis showed that HLA-alloimmunization was significantly 
      reduced by leukocyte-filtered platelet transfusion among the patients with acute 
      myelocytic leukemia [ RR =0.42, 95% CI (0.32, 0.56), P <0. 00001], while no 
      significant difference was detected in patients with acute lymphoblastic leukemia 
      because of the limited sample size [ RR = 0. 50, 95% CI (0. 10, 2.41) , P =0. 
      39]. CONCLUSIONS: The current evidence shows that leukocyte-filtered platelet 
      transfusion can prevent PTR and HLA-alloimmunization more effectively than 
      standard platelet transfusion. Well-designed large-scale RCTs are still needed to 
      further confirm this finding.
FAU - Yuan, Qiang
AU  - Yuan Q
AD  - West China Hospital, Sichuan University, Chengdu, China.
FAU - Chen, Xue
AU  - Chen X
FAU - Cheng, Lan
AU  - Cheng L
FAU - Zhou, Chang-hua
AU  - Zhou CH
FAU - Fu, Xue-mei
AU  - Fu XM
FAU - Li, You-ping
AU  - Li YP
FAU - Wang, Nai-hong
AU  - Wang NH
FAU - Wang, Li
AU  - Wang L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Filtration
MH  - HLA Antigens/immunology
MH  - Humans
MH  - *Leukocytes/immunology
MH  - Platelet Transfusion/*methods
MH  - Randomized Controlled Trials as Topic
EDAT- 2011/09/13 06:00
MHDA- 2013/10/30 06:00
CRDT- 2011/09/13 06:00
PHST- 2011/09/13 06:00 [entrez]
PHST- 2011/09/13 06:00 [pubmed]
PHST- 2013/10/30 06:00 [medline]
AID - 10.3881/j.issn.1000-503X.2011.04.013 [doi]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Aug;33(4):412-20. doi: 
      10.3881/j.issn.1000-503X.2011.04.013.